EAM
NKTR icon

Exome Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Exome Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-75,000
Closed -$1.94M – 89
2025
Q2 		$1.94M Buy
75,000
+70,000
+1,400% +$786K 1.44% 27
2025
Q1 		$22.5K Buy
+5,000
New +$65.3K 0.02% 56

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Exome Asset Management's NKTR Position: Q2 2026 in Review

Exome Asset Management opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 22,417 shares worth $1.56M. The stake represents 0.97% of the portfolio and ranks #39 among its holdings. This is a return to the name: Exome Asset Management previously reported a position in NKTR as recently as Q1 2025.

Exome Asset Management first reported a position in NKTR in Q4 2024 and has held it in 3 quarters since. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Exome Asset Management held 22,417 shares of Nektar Therapeutics worth $1.56M as of Q2 2026.
  • Nektar Therapeutics was a new Exome Asset Management position in Q2 2026.
  • Nektar Therapeutics made up 0.97% of Exome Asset Management's portfolio in Q2 2026, its #39 holding.
  • Exome Asset Management first reported a position in Nektar Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.